Critical illness-related corticosteroid insufficiency history and symptoms
|
Critical illness-related corticosteroid insufficiency Microchapters |
|
Differentiating Critical illness-related corticosteroid insufficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Critical illness-related corticosteroid insufficiency history and symptoms On the Web |
|
American Roentgen Ray Society Images of Critical illness-related corticosteroid insufficiency history and symptoms |
|
FDA on Critical illness-related corticosteroid insufficiency history and symptoms |
|
CDC on Critical illness-related corticosteroid insufficiency history and symptoms |
|
Critical illness-related corticosteroid insufficiency history and symptoms in the news |
|
Blogs on Critical illness-related corticosteroid insufficiency history and symptoms |
|
Directions to Hospitals Treating Critical illness-related corticosteroid insufficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
History
Symptoms
The best known feature that suggests a possible underlying adrenal insufficiency is low blood pressure despite resuscitation with intravenous fluids, requiring vasopressor drugs. These patients typically display tachycardia and other signs of hyperdynamic shock. Other symptoms include fever, purpura fulminans, and gastrointestinal or neurological disturbances. All these features are relatively non-specific in intensive care patients.
In some patients a specific reason for adrenal insufficiency can be suspected, such as prior intake of corticosteroids that suppressed the HPA axis, or use of enzyme inducing drugs such as phenytoin. Treatment with imidazole drugs such as etomidate, ketoconazole and miconazole can also suppress the HPA axis, as well as drugs used specifically for this purpose, such as metyrapone.Lamberts SW, Bons EG, Bruining HA, de Jong FH (1987). "Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells". J. Pharmacol. Exp. Ther. 240 (1): 259–64. PMID 3027305. Unknown parameter |month= ignored (help)</ref>